Comments
AstraZeneca Pharma India Limited has received import and market permission in Form CT-20 (Marketing Authorisation-Additional Indication) from the Drugs Controller General of India for Benralizumab 30mg/mL solution for injection (Fasenra).
In a regulatory filing to the exchanges, the company said Benralizumab 30mg/mL injection (Fasenra) was launched in India on April 20. Fasenra is indicated as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in adult patients.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.